NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

特發性嗜睡症治療的市場規模:各藥物類別、流通管道、地區 - 佔有率,展望,機會分析(2020年∼2027年)

Idiopathic Hypersomnia Treatment Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 979993
出版日期 內容資訊 英文 180 Pages
商品交期: 2-3個工作天內
價格
特發性嗜睡症治療的市場規模:各藥物類別、流通管道、地區 - 佔有率,展望,機會分析(2020年∼2027年) Idiopathic Hypersomnia Treatment Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年12月18日內容資訊: 英文 180 Pages
簡介

全球特發性嗜睡症治療市場主要成長要素,是開發中產品數的增加和文明病的病例增加等。特發性嗜睡症是稀少的睡眠疾病,即使經過一夜安眠,白天可能過於睏倦。還有夜晚的睡眠和午睡後,患者的覺醒變得困難。對特發性嗜睡症雖然有對症療法,但是沒有對這個疾病的已批准單一藥物。

本報告提供全球特發性嗜睡症治療市場的相關調查,市場機會和趨勢,成長及阻礙因素,各醫藥品分類、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各醫藥品分類
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,及趨勢分析

  • CKD階段治療選擇
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 市場趨勢
  • 最近的產品銷售/核准
  • 治療費
  • 法規方案
  • PEST分析
  • 合併,收購,及聯盟
  • 流行病學
  • 償付方案(醫療保險D部分支出)

第4章 Covid-19大流行的影響

  • 經濟影響
  • 需求與供給分析
  • 研究開發
  • 政府的積極推動

第5章 市場分析:各醫藥品分類(2016-2027)

  • 簡介
  • 興奮劑
  • 非興奮劑覺醒促進藥
  • Sodium Oxybate

第6章 市場分析:各流通管道(2016-2027)

  • 簡介
  • 醫院藥局
  • 線上藥局
  • 零售藥局

第7章 市場分析:各地區(2016-2027)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Jazz Pharmaceuticals, Inc.
    • BIOPROJET
    • Avadel Pharmaceuticals, Plc.
    • GlaxoSmithKline plc,
    • Pfizer Inc.
    • Theranexus
    • Fisher & Paykel Healthcare Limited
    • Innovation Pharmaceuticals Inc.
    • Drive DeVilbiss Healthcare LLC
    • Merck & Co. Inc.

第9章 Section

目錄

Title:
Idiopathic Hypersomnia Treatment Market, by Drug Class (Stimulant Medications, Non-stimulant wake-promoting Medications, and Sodium Oxybate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Idiopathic hypersomnia is a rare sleep disease that causes a person to be excessively sleepy during the day even after a good or prolonged night's sleep. It also causes difficulty in waking up among patients after a night sleep or a nap. Moreover, narcolepsy and idiopathic hypersomnia are both types of hypersomnia but there are differences, which can be observed by diagnostic tests such as Polysomnography (PSG) that lies in the number of sleep-onset REM periods (SOREMPs). Patients with narcolepsy have two or more SOREMPs from Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, whereas patients with idiopathic hypersomnia do not. There are symptomatic treatment such as increase wakefullness options available for idiopathic hypersomnia, while there is not a single approved drugs for this disease.

Market Dynamics

Rising number of pipeline products and increasing cases of lifestyle diseases are some of the major factors responsible for growth of the global idiopathic hypersomnia treatment Market. For instance, in October 2020, Jazz Pharmaceuticals announced positive topline results from a phase 3 study evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic hypersomnia that showed that the trial met the primary point (measured Epworth Sleepiness Scale (ESS) and key secondary end points [Patient Global Impression of Change (PGIc) and Idiopathic Hypersomnia Severity Scale (IHSS)].

Key features of the study:

  • This report provides in-depth analysis of the global idiopathic hypersomnia treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global idiopathic hypersomnia treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global idiopathic hypersomnia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global idiopathic hypersomnia treatment Market

Detailed Segmentation:

  • Global Idiopathic Hypersomnia Treatment Market, By Drug Class:
    • Stimulant Medications
    • Non-stimulant wake-promoting Medications
    • Sodium Oxybate
  • Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Idiopathic Hypersomnia Treatment Market, By Region:
    • North America
      • By Drug Class:
      • Stimulant Medications
      • Non-stimulant wake-promoting Medications
      • Sodium Oxybate
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Class:
      • Stimulant Medications
      • Non-stimulant wake-promoting Medications
      • Sodium Oxybate
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class:
      • Stimulant Medications
      • Non-stimulant wake-promoting Medications
      • Sodium Oxybate
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • Stimulant Medications
      • Non-stimulant wake-promoting Medications
      • Sodium Oxybate
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
      • Stimulant Medications
      • Non-stimulant wake-promoting Medications
      • Sodium Oxybate
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • Stimulant Medications
      • Non-stimulant wake-promoting Medications
      • Sodium Oxybate
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Jazz Pharmaceuticals, Inc.
    • BIOPROJET
    • Avadel Pharmaceuticals, Plc.
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Theranexus
    • Fisher & Paykel Healthcare Limited
    • Drive DeVilbiss Healthcare LLC
    • Merck & Co. Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • CKD Stages Treatment Options
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Market Trends
  • Recent Product Launch/Approvals
  • Cost of Treatment
  • Regulatory Scenario
  • PEST Analysis
  • Mergers, Acquisitions, and Partnerships
  • Epidemiology
  • Reimbursement Scenario (Medicare Part D Spending)

4. Global Idiopathic Hypersomnia Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • Supply and Demand Analysis
  • Research and Development
  • Government Initiatives

5. Global Idiopathic Hypersomnia Treatment Market, By Drug Class, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Stimulant Medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Non-stimulant wake-promoting Medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Sodium Oxybate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Idiopathic Hypersomnia Treatment Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Jazz Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • BIOPROJET
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Avadel Pharmaceuticals, Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc,
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Theranexus
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Fisher & Paykel Healthcare Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Innovation Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Drive DeVilbiss Healthcare LLC
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies

9. Section

  • Research Methodology
  • About us and Sales Contact